https://orcid.org/0000-0003-0796-0496
Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, Joseph Azuri & Ronen Arbel. (2022) Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6. Postgraduate Medicine 134:7, pages 654-658.
Read now
Read now
Ofri Mosenzon, Eden M. Miller & Mark L. Warren. (2020) Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Postgraduate Medicine 132:sup2, pages 37-47.
Read now
Read now
Frank Lavernia & Lawrence Blonde. (2020) Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgraduate Medicine 132:sup2, pages 15-25.
Read now
Read now
Eugene E. Wright Jr & Vanita R. Aroda. (2020) Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgraduate Medicine 132:sup2, pages 26-36.
Read now
Read now
Stephen A. Brunton & Carol H. Wysham. (2020) GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgraduate Medicine 132:sup2, pages 3-14.
Read now
Read now
Articles from other publishers (9)
Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, Monika Różycka-Kosmalska & Tadeusz Pietras. (2023) Pharmacological Support for the Treatment of Obesity—Present and Future. Healthcare 11:3, pages 433.
Crossref
Crossref
Yousef Alhindi & Amanda Avery. (2022) The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. Contemporary Clinical Trials Communications 28, pages 100944.
Crossref
Crossref
Shashank R. Joshi, Rajesh Rajput, Subhankar Chowdhury, Awadhesh K. Singh, Ganapathi Bantwal, Ashok K. Das, A.G. Unnikrishnan, Banshi D. Saboo, Jothydev Kesavadev, Samit Ghosal & Viswanathan Mohan. (2022) The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:6, pages 102508.
Crossref
Crossref
Manoj Kumar Mahapatra, Muthukumar Karuppasamy & Biswa Mohan Sahoo. (2022) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders 23:3, pages 521-539.
Crossref
Crossref
Marc Evans, Angharad R. Morgan, Stephen C. Bain, Sarah Davies, Debbie Hicks, Pam Brown, Zaheer Yousef, Umesh Dashora, Adie Viljoen, Hannah Beba & W. David Strain. (2022) Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Therapy 13:2, pages 225-240.
Crossref
Crossref
Sanjay Kalra, Sambit Das & AbdulH Zargar. (2022) A review of oral semaglutide available evidence: A new era of management of diabetes with peptide in a pill form. Indian Journal of Endocrinology and Metabolism 26:2, pages 98.
Crossref
Crossref
Carlos Escobar, Almudena Castro, Jorge Francisco Gómez Cerezo, José Luis Górriz, Juan Carlos Obaya Rebollar & Rocío Villar-Taibo. (2022) Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2. Revista Española de Cardiología Suplementos 22, pages 1-9.
Crossref
Crossref
Agni Kakouri, Georgia Kanti, Efthymios Kapantais, Alexandros Kokkinos, Leonidas Lanaras, Paul Farajian, Christos Galanakis, Georgios Georgantopoulos, Nikos F. Vlahos, George Mastorakos, Alexandra Bargiota & Georgios Valsamakis. (2021) New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review. Pharmaceuticals 14:9, pages 869.
Crossref
Crossref
Mariana Cornelia Tilinca, Robert Aurelian Tiuca, Alexandru Burlacu & Andreea Varga. (2021) A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review. Medicina 57:7, pages 669.
Crossref
Crossref